Results 11 to 20 of about 3,785 (146)

A case of successful contribution of therapeutic drug monitoring of valganciclovir as the prophylaxis against cytomegalovirus infection in a lung transplant recipient

Journal of Pharmaceutical Health Care and Sciences
Background Ganciclovir and its prodrug, valganciclovir, are first-line agents for cytomegalovirus infection prophylaxis after lung transplantation. Although valganciclovir prophylaxis is known to result in severe leukopenia as an adverse effect, dosage ...
Yoshiki Katada, Keisuke Umemura, Shunsaku Nakagawa, Yurie Katsube, Masahiro Tsuda, Satona Tanaka, Hiroshi Date, Miki Nagao, Tomohiro Terada   +8 more
doaj   +2 more sources

Oral valganciclovir in human immunodeficiency virus-positive patients suffering from cytomegalovirus retinitis at a tertiary care hospital in North India

Indian Journal of Ophthalmology, 2022
Purpose: To study clinical efficacy of valganciclovir in cytomegalovirus retinitis (CMVR) in human immunodeficiency virus (HIV)-positive-positive patients in a tertiary care clinic in a developing nation.
Ashish Markan, Nikita Gupta, Mohit Dogra, Aman Sharma, Ramandeep Singh   +4 more
doaj   +2 more sources

Valganciclovir as Add-on to Second-Line Therapy in Patients with Recurrent Glioblastoma

Cancers, 2022
Simple Summary Patients with glioblastoma have a dismal prognosis. The major challenge with this disease is that it recurs despite aggressive first-line therapy and rapidly becomes therapy resistant.
Mattia Russel Pantalone, Afsar Rahbar, Cecilia Söderberg-Nauclér   +2 more
exaly   +2 more sources

Oral Administration of Valganciclovir Reduces Clinical Signs, Virus Shedding and Cell-Associated Viremia in Ponies Experimentally Infected with the Equid Herpesvirus-1 C₂₂₅₄ Variant

Pathogens, 2022
Equid alphaherpesvirus-1 (EHV-1) is one of the main pathogens in horses, responsible for respiratory diseases, ocular diseases, abortions, neonatal foal death and neurological complications such as equine herpesvirus myeloencephalopathy (EHM).
Côme J. Thieulent, Gabrielle Sutton, Marie-Pierre Toquet, Samuel Fremaux, Erika Hue, Christine Fortier, Alexis Pléau, Alain Deslis, Stéphane Abrioux, Edouard Guitton, Stéphane Pronost, Romain Paillot   +11 more
doaj   +2 more sources

Treatment of cytomegalovirus anterior segment infection with intravitreal injection of ganciclovir in adjunction with or without oral valganciclovir: a long-term results

Scientific Reports, 2021
We evaluated the therapeutic outcome of intravitreal injection (IVI) of ganciclovir with/without oral valganciclovir for cytomegalovirus (CMV) anterior segment infection.
Yu-Chun Cheng, Eugene Yu-Chuan Kang, Yih-Shiou Hwang, Ching-Hsi Hsiao   +3 more
doaj   +2 more sources

Maribavir for Cytomegalovirus Infection in High‐Risk Kidney Transplant Recipients: A Case Series

IJU Case Reports
Background Cytomegalovirus (CMV) infection remains a common complication after kidney transplantation, particularly among high‐risk donor‐seropositive/recipient‐seronegative (D+/R−) recipients.
Daiji Takamoto, Yu Shimada, Yuri Hasegawa, Takeaki Noguchi, Takashi Kawahara, Junichi Teranishi, Kazuhide Makiyama   +6 more
doaj   +2 more sources

Evaluation of neutropenia secondary to mycophenolate mofetil associated with valganciclovir in liver transplant patients [PDF]

Farmacia Hospitalaria, 2021
Objective: Immunosuppressive drugs are necessary to avoid or reduce the risk of rejection of transplanted organs. The immunosuppression generated may result in these patients needing antibiotics and antivirals to be prescribed to them in conjunction ...
Alejandro Ferrer-Machín, Martín Vera-Cabrera, Inmaculada Plasencia-García, Antonia Moreno-García, Lina I. Pérez-Méndez, Javier Merino-Alonso   +5 more
doaj   +1 more source

Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2023
Importance Valganciclovir for 200 days is standard care for cytomegalovirus (CMV) prophylaxis in high-risk CMV-seronegative kidney transplant recipients who receive an organ from a CMV-seropositive donor, but its use is limited by myelosuppression ...
A. Limaye, K. Budde, A. Humar, F. Vincenti, D. Kuypers, R. Carroll, Nicole Stauffer, Y. Murata, J. Strizki, V. Teal, C. Gilbert, B. Haber   +11 more
semanticscholar   +1 more source

Valganciclovir [PDF]

Reactions Weekly, 2021
  +10 more sources

Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation

Therapeutic Advances in Hematology, 2021
Background: Letermovir prophylaxis is currently the standard of care for the prevention of cytomegalovirus (CMV) infections in allogeneic hematopoietic stem-cell transplantation (allo-HSCT).
Po-Hsien Li, Cheng-Hsien Lin, Yu-Hui Lin, Tsung-Chih Chen, Chiann-Yi Hsu, Chieh-Lin Jerry Teng   +5 more
doaj   +1 more source